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a  b  s  t  r  a  c  t
This  retrospective  observational  study  evaluated  cost  effectiveness  of  ﬁrst-line  treatment  of  advanced
nonsquamous  non-small  cell  lung  cancer  (NSCLC)  with  pemetrexed/platinum  (Pem/Plat)  relative  to
paclitaxel/carboplatin  (Pac/Carbo)  and  paclitaxel/carboplatin/bevacizumab  (Pac/Carbo/Bev).  Patients  ini-
tiating  ﬁrst-line  treatment  from  2006  to 2009  were  identiﬁed  in  electronic  medical  records  of  20 US
oncology  practices.  Pem/Plat  patients  were  matched  1:1  on  important  characteristics  with  Pac/Carbo  and
Pac/Carbo/Bev  patients  and  followed  for  1 year  to  assess  progression,  survival,  and  costs.  Bootstrapping
was  used  to calculate  the probability  of  falling  within  quadrants  of  the  incremental  cost-effectiveness
plane. Kaplan–Meier  analysis  and  Cox  proportional  hazards  regression  modeling  were  also  performed.
Three  hundred  Pem/Plat  patients  (mean  age,  67.6 years;  male,  56.0%;  PS 0/1,  71.0%)  were  matched  with
300  patients  in the  other  cohorts.  Median  PFS  was  134  days  (Pem/Plat)  versus  106  days  (Pac/Carbo)  (haz-
ard  ratio [HR]:  0.67,  P <  0.001)  and  126  days  (Pac/Carbo/Bev)  (HR:  0.68,  P  <  0.001).  Median  OS  was  298
days  (Pem/Plat)  versus  218 days  (Pac/Carbo)  (HR:  0.88, P = 0.08)  and  271  days  (Pac/Carbo/Bev)  (HR: 0.93,
P  =  0.31).  Pem/Plat  therapy  costs  were  higher  versus  Pac/Carbo  ($21,841  higher  PFS;  $19,137  higher  OS;
P  ≤ 0.05)  and lower  versus  Pac/Carbo/Bev  ($15,160  lower  PFS;  $19,946  lower  OS;  P ≤  0.05).  Pem/Plat  had
a  greater  probability  of higher  costs/higher  effectiveness  versus  Pac/Carbo  (PFS,  90.1%;  OS,  96.3%)  and
lower costs/higher  effectiveness  versus  Pac/Carbo/Bev  (PFS,  69.5%;  OS,  85.0%).  Pem/Plat  had  higher  cost
and effectiveness  than  Pac/Carbo;  depending  on  a  payer’s  or society’s  willingness  to pay,  Pem/Plat  may
be  considered  cost  effective  compared  with  Pac/Carbo.  Pem/Plat  yielded  greater  effectiveness  with  lower
.
he Aucosts than  Pac/Carbo/Bev
© 2013 T
. IntroductionLung cancer is the second most commonly diagnosed cancer
mong both men  and women in the United States (US) and is the
eading cause of cancer deaths in both genders [1]. Non-small cell
 Some of the study results (pemetrexed-platinum data) were presented at the
4th annual meeting of the Academy of Managed Care Pharmacy, San Francisco, CA,
SA; April 18–20, 2012. The pemetrexed-cisplatin subgroup results were presented
t the 37th Congress of the European Society for Medical Oncology, Vienna, Austria;
eptember 28–October 2, 2012.
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lung cancer (NSCLC) constitutes 80–85% of all lung cancers [2].
An estimated 78% of NSCLCs are detected as advanced (regional
or distant) disease according to the US National Cancer Institute
Surveillance and Epidemiology and End Results (NCI SEER) staging
distribution data for 2002–2008 [3]. Among patients with advanced
disease (stage IIIB/IV), prognosis remains poor, with 5-year survival
estimated at 15.9% [3].
For patients with advanced (stage IIIB/IV) NSCLC, clinical
guidelines recommend the use of 2-drug combination regimens as
ﬁrst-line therapy [4,5]. First-line treatment is often a combination
therapy using platinum plus taxane-based chemotherapeutic
agents with or without biologics or platinum plus targeted
small-molecule therapy. Recent evidence from various phase
III clinical trials has demonstrated the efﬁcacy of speciﬁc com-
Open access under CC BY-NC-SA license. bination treatments like pemetrexed/cisplatin (Pem/Cis) and
paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev) in the ﬁrst-
line setting for patients with advanced nonsquamous NSCLC
[6,7]. Despite lack of data from phase III trials directly comparing
-NC-SA license. 
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Table 1
Variables used to match cohorts.
Variable Number of strata Description
Index year 4 2006, 2007, 2008, 2009
AJCC stage 5 Stage I with subsequent
progression to advanced disease
Stage II with subsequent
progression to advanced disease
Stage IIIA with subsequent
progression to advanced disease
Diagnosed advanced stage IIIB
Diagnosed advanced stage IV
Gender 2 Male
Female
Performance status 3 ECOG 0
ECOG 1
ECOG 2+
Age, years 6 <40
40–49
50–59
60–69
70–79
80+
domly matched to one Pac/Carbo patient and one Pac/Carbo/Bev
patient.
Table 2
Clinical and demographic characteristics of patients.
Variable Pem/Plat N = 300 Pem/Cis N = 78
N % N %
Platinum
Carboplatin 222 74.0 0 0.0
Cisplatin 78 26.0 78 100.0
Age
<40  4 1.3 2 2.6
40–49 21 7.0 6 7.7
50–59 66 22.0 17 21.8
60–69 101 33.7 26 33.3
70–79 91 30.3 23 29.5
80+  17 5.7 4 5.1
Gender
Male 168 56.0 46 59.0
Female 132 44.0 32 41.0
Stage at diagnosis
I 5 1.7 0 0.0
II  7 2.3 2 2.6
IIIA  10 3.3 3 3.8
IIIB  75 25.0 35 44.9
IV  203 67.7 38 48.7
Index ECOG PSa
0 81 27.0 17 21.8
1  132 44.0 44 56.4
2  75 25.0 17 21.8
3  9 3.0 0 0.022 M. Shah et al. / Lung 
linical outcomes associated with Pem/Cis with Pac/Carbo and
ac/Carbo/Bev, these three regimens are frequently used in clinical
ractice as ﬁrst-line treatment. Additionally, to our knowledge,
ew studies have used real-world data to compare the clinical and
conomic outcomes associated with these treatment strategies.
The primary objective of this retrospective observational study
as to examine the real-world incremental cost effectiveness of a
rst-line chemotherapy regimen with pemetrexed plus platinum
Pem/Plat therapy) combination relative to the Pac/Carbo combi-
ation (doublet) and the Pac/Carbo/Bev combination (triplet) in
atients with advanced nonsquamous NSCLC in the US outpatient
edical oncology setting.
. Patients and methods
.1. Data source
This retrospective cohort study used data captured within the
nternational Oncology Network (ION) clinical oncology database
rom January 2006 through December 2010. This electronic medi-
al records (EMR) database captures outpatient-practice encounter
istory for patients under care of 175 geographically dispersed
roviders, representing 20 large, community-based practices
cross 13 states. The database includes laboratory results, diag-
osis, disease proﬁle, anthropomorphic measures, vital signs,
reatment plan, speciﬁc therapy administrations associated with
reatment plans, other medications such as supportive care agents,
nd performance status. The data elements described above are
ypically captured through either standardized ﬁelds or electronic
rogress notes. For purposes of this study, electronic progress
otes were reviewed to abstract and/or verify information on
ecessary clinical and demographic characteristics, including
dvanced disease status, histology, and other inclusion criteria.
In addition to clinical EMR  data, practice management system
PMS) data are incorporated within the EMR  database; these data
nclude patient demographics, treatment given, diagnosis informa-
ion, dates, and billed transactions from the outpatient medical
ncology setting. Utilization outside of this setting (e.g., hospital-
zations and emergency department visits) is not captured. The
ocial Security Death Index (Social Security Administration’s [SSA]
aster Death File) was used to supplement documented vital sta-
us [8]. All data access, use, and reporting were conducted in
 manner compliant with the Health Insurance Portability and
ccountability Act, ensuring that conﬁdentiality and privacy of
atients were maintained. In addition, the use of patient data for
his study was approved by an independent, central institutional
eview board.
.2. Patient selection
The target population was patients with advanced nonsqua-
ous NSCLC who initiated ﬁrst-line treatment between January
006 and December 2009 (i.e., study enrollment period). To be
ligible for analysis, patients were required to meet the follow-
ng criteria: (1) be at least 18 years of age, (2) have at least one
nternational Classiﬁcation of Diseases, Ninth Revision, Clinical
odiﬁcation (ICD-9-CM) diagnosis code for lung cancer (162.2,
62.3, 162.4, 162.5, 162.8, 162.9, 197.0, or 231.2) along with docu-
ented advanced disease (stage IIIB/IV or early stage with evidence
f progression to advanced disease), and (3) initiate ﬁrst-line
hemotherapy with or without targeted therapy (i.e., Pem/Plat,
ac/Carbo, or Pac/Carbo/Bev after documentation of advanced dis-
ase). The date of ﬁrst-line treatment was deﬁned as the index date.
atients were excluded based on the following criteria: (1) receiv-
ng care for another primary cancer during the study period, (2)
quamous cell histology, (3) enrollment in clinical trials during theAbbreviations:  AJCC, American Joint Committee on Cancer; ECOG, Eastern Coopera-
tive Oncology Group.
study period, (4) follow-up time of less than 1 year and no evidence
of disease progression/death.
Eligible patients were placed into the following cohorts based
on ﬁrst-line treatment initiation: (1) Pem/Plat, (2) Pac/Carbo dou-
blet, or (3) Pac/Carbo/Bev triplet. To mitigate any potential bias due
to differences in patient characteristics, a matching strategy was
employed. Patients in each cohort were placed into speciﬁc strata
based on ﬁve key variables listed in Table 1. Within each strata
(e.g., index year 2007, advanced stage IV, male, performance status
score of 1, and age bracket 40–49), a Pem/Plat patient was ran-4  3 1.0 0 0.0
Abbreviations:  ECOG PS, Eastern Cooperative Oncology Group performance status;
Pem/Cis, pemetrexed plus cisplatin; Pem/Plat, pemetrexed plus platinum.
a Index = date of ﬁrst-line therapy initiation.
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Table 3
Clinical outcomes in matched cohorts.
Parameter overall population (Pem/Plat comparisons) N = 300 per cohort
Pem/Plat Pac/Carbo Pac/Carbo/Bev
PFS events 258 279 282
PFS  mean, days 136 103 125
Difference versus Pem/Plat, days (95% CI) NA 33 (−15.4, 89.4) 11 (−33.8, 70.4)
PFS  median, days 134 106 126
Log-rank p-value, versus Pem/Plat NA < 0.001 < 0.001
HRa (95% CI) NA 0.67 (0.53, 0.83) 0.68 (0.53, 0.83)
OS  events 198 222 216
OS  mean, days 190 132 163
Difference versus Pem/Plat, days (95% CI) NA 58 (−4.6, 121.1) 27 (−23.9, 87.6)
OS  median, days 298 218 271
Log-rank p-value, versus Pem/Plat NA 0.08 0.31
HRa (95% CI) NA 0.88 (0.67, 1.08) 0.93 (0.75, 1.14)
Parameter subgroup (Pem/Cis comparisons) N = 78 per cohort
Pem/Cis Pac/Carbo Pac/Carbo/Bev
PFS events 68 73 75
PFS  mean, days 147 108 132
Difference versus Pem/Cis, days (95% CI) NA 39 (−23.5, 99.7) 15 (−53.3, 82.3)
PFS  median, days 128 105 112
Log-rank p-value, versus Pem/Plat NA 0.004 0.007
HRa (95% CI) NA 0.70 (0.51, 0.97) 0.66 (0.47, 0.93)
OS  events 46 59 55
OS  mean, days 202 145 172
Difference versus Pem/Cis, days (95% CI) NA 57 (−8.4, 134.6) 30 (−44.0, 98.6)
OS  median, days 327 234 279
Log-rank p-value, versus Pem/Plat NA 0.10 0.19
HRa (95% CI) NA 0.82 (0.65, 1.03) 0.87 (0.70, 1.07)
Abbreviations: Bev, bevacizumab; Carbo, carboplatin; CI, conﬁdence interval; HR, hazard ratio; NA, not applicable; Pac, paclitaxel; Pem/Cis, pemetrexed plus cisplatin;
Pem/Plat, pemetrexed plus platinum; PFS, progression-free survival; OS, overall survival.
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aa Adjusted for smoking status.
.3. Outcomes
Patients were followed for 1 year after the index date to cap-
ure the outcomes of interest. The primary effectiveness measures
ncluded progression-free survival (PFS) and overall survival (OS).
rogression was identiﬁed and/or veriﬁed through chart review
nd was deﬁned as a treatment change indicative of disease
rogression or documented disease progression. In cases of uncer-
ainty of disease progression, a clinical expert (Dr. Mark Green)
onﬁrmed progression status. Date of death was captured from the
SA Death Index Master File in combination with date of death in
he ION EMR  data. PFS and OS were calculated as the time between
rst-line treatment initiation date and the earliest of the following
ates: (1) date of progression (for PFS), (2) date of death, (3) end
f the 1-year observation period. As described in the patient exclu-
ion criteria, patients with censored follow-up of less than 1 year
ith no evidence of disease progression or death were excluded
rom the analysis. The primary cost measures included progression-
ree costs and overall costs. Costs were based on all billed charges
ocumented in the PMS  data and were obtained for chemother-
py administration, supportive care, and other costs. Supportive
are costs included charges for erythropoietin-stimulating agents,
hite blood cell growth factors, and bisphosphonates. Other costs
ncluded charges for facility costs, physician and nursing fees
ot included in chemotherapy administration costs, and other
ncillary drug and service costs (e.g., laboratory tests and diagnos-
ics)..4. Statistical methods
Incremental effectiveness was measured as the difference in PFS
nd OS within each matched pair. Incremental costs were measuredas differences in costs during the PFS/OS periods for each matched
pair. Mean differences in effectiveness and costs were calculated
for each matching strata. An overall mean was calculated as the
weighted average of the strata-speciﬁc differences (weighted by
the relative proportional sizes of the strata) in effectiveness and
cost.
Traditional survival analyses (Kaplan–Meier analysis and Cox
proportional hazards regression modeling) were conducted to
estimate and compare PFS and OS between treatment cohorts.
These analyses were repeated for those patients who received
Pem/Cis as well as for patients with an Eastern Cooperative
Oncology Group performance factor (ECOG PS) 0/1 who received
Pem/Cis.
Statistical inference associated with the mean difference in cost
effectiveness and individual component variables of effectiveness
and cost were determined using a bootstrap method, in which the
matched pairs in the study population were randomly re-sampled
(5000 samples with replacement) [9]. The random re-sampling
was done such that, for each sample the same method of esti-
mation for strata mean values and overall mean values of cost
effectiveness was  repeated as described above for the point esti-
mates. Re-sampling and re-analysis provided an ordered empirical
sampling distribution for each mean value, and central 95% conﬁ-
dence intervals (CIs) were constructed using the 2.5th and 97.5th
percentiles of each statistic’s empirical sampling distribution. The
bootstrapped samples were used to calculate probability for each
incremental cost-effectiveness pair falling into any particular quad-
rant of the incremental cost-effectiveness plane as a proportion of
the empirical distribution lying in that quadrant. Statistical analy-
ses were performed using SAS® software, Version 9.1 (SAS Institute
Inc., Cary, NC, USA).
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Table  4
Cost data in matched cohorts.
N = 300 per cohort
PFS OS
Pem/Plat Pac/Carbo Pac/Carbo/Bev Pem/Plat Pac/Carbo Pac/Carbo/Bev
Overall costsa
Mean $33,745 $11,904 $48,905 $33,969 $14,832 $53,915
Std  dev $37,719 $12,469 $49,541 $34,631 $15,550 $54,267
Diff  vs Pem/Plat NA −$21,841 $15,160 NA −$19,137 $19,946
95%  CI −$32,052, −$11,921 $2,817, $27,547 −$28,642, −$9562 $6074, $33,874
Mean  incremental cost/day (for Pem/Plat) NA $662 −$1378 NA $330 −$739
95%  CI $497, $916 −$1658, −$1144 $241, $466 −$843, −$637
Cost  components
Chemotherapy, mean $28,799 $6728 $42,079 $28,935 $8500 $45,835
Std  dev $32,575 $6900 $45,326 $33,819 $9207 $47,144
Supportive care, mean $3750 $2653 $5318 $3764 $3385 $5936
Std  dev $4541 $4224 $7482 $4568 $4871 $8029
Other costs, meanb $1196 $2524 $1508 $1270 $2947 $2144
Std  dev $3355 $5832 $3495 $3563 $7200 $3735
N  = 78 per cohort
PFS OS
Pem/Cis Pac/Carbo Pac/Carbo/Bev Pem/Cis Pac/Carbo Pac/Carbo/Bev
Overall costsa
Mean $40,102 $14,519 $57,705 $43,259 $18,148 $61,475
Std  dev $37,942 $15,172 $57,571 $43,662 $19,221 $63,375
Diff  vs Pem/Cis NA $−25,583 $17,603 NA $−25,111 $18,216
95%  CI $−38,741, $−15,601 $3269, $28,565 $−30,627, $−9987 $3889, $33,306
Mean  incremental cost/day (for Pem/Cis) NA $656 $−1174 NA $441 −$607
95%  CI NA $494, $913 $−1347, $−1001 NA $326, $608 $−676, $−506
Cost  components
Chemotherapy, mean $31,262 $8213 $49,478 $33,162 $10,962 $52,086
Std  dev $30,458 $8984 $50,014 $35,050 $11,381 $54,809
Supportive care, mean $5402 $3630 $6408 $6122 $4366 $6803
Std  dev $7746 $5175 $8518 $8913 $6021 $9004
Other costs, meanb $3438 $2676 $1820 $3975 $2820 $2586
Std  dev $8683 $7025 $3963 $9992 $8900 $4218
Abbreviations:  Bev, bevacizumab; Carbo, carboplatin; CI, conﬁdence interval; diff, difference; NA, not applicable; Pac, paclitaxel; Pem/Cis, pemetrexed plus cisplatin; Pem/Plat,
pemetrexed plus platinum; std dev, standard deviation.
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6a Cost component totals were obtained by adding unrounded components.
b Other costs included charges for facility costs, physician and nursing fees not in
e.g.,  laboratory tests and diagnostics).
. Results
.1. Patient characteristics
A total of 481 patients received Pem/Plat therapy during the
tudy period. Following chart review of these patients, we veriﬁed
hat 300 were ﬁrst-line Pem/Plat patients with advanced cancer
nd met  all inclusion criteria. Matched patients for the Pac/Carbo
oublet were selected from 2599 potentially eligible patients, and
ac/Carbo/Bev triplet patients were selected from 694 potentially
ligible patients. The matching strategy resulted in a total cost-
ffectiveness study population of 900 patients (N = 300 Pem/Plat
atients and N = 300 patients for each of the comparator cohorts). Of
he 300 Pem/Plat patients, 78 received Pem/Cis and were matched
ith 78 Pac/Carbo patients and 78 Pac/Carbo/Bev patients.
The distribution of matching characteristics across the Pem/Plat
ohort is presented for the overall population, as well as for
he subset of Pem/Cis patients, in Table 2. Because of successful
atching, patients in the comparator cohorts were identical with
espect to these variables. Most Pem/Plat patients received carbo-
latin (n = 222, 74.0%) as compared with cisplatin (n = 78; 26.0%). In
omparison, 100% of the doublet and triplet comparator patients
eceived carboplatin. The mean age of Pem/Plat patients was 67.6
ears, and a large proportion (64.0%) fell within the age range of
0–79 years. Only a small number (n = 22; 7.3%) of Pem/Plat patientsd in chemotherapy administration costs, and other ancillary drug and service costs
were initially diagnosed with lower-stage disease (I–IIIA) and sub-
sequently progressed to advanced disease. Most Pem/Plat patients
(71.0%) had a PS of 0 or 1. Similar distributions were observed for the
subset of patients receiving Pem/Cis; a large majority (62.8%) were
60–79 years old (mean age = 64.1 years), 5 patients (6.4%) were ini-
tially diagnosed with lower-stage disease (I–IIIA), and 78.2% had a
PS of 0 or 1.
The distribution of other clinical characteristics showed differ-
ences across the Pem/Plat, Pac/Carbo, and Pac/Carbo/Bev cohorts.
The triplet cohort had the highest mean number of cycles admin-
istered (6.62 cycles) compared with Pac/Carbo doublet (5.04
cycles) or Pem/Plat (4.12 cycles). The triplet cohort also had a
slightly higher percentage of never smokers (17.7%) compared with
Pem/Plat (14.7%) or Pac/Carbo doublet (12.3%). Similar trends were
observed in the subset of Pem/Cis and matched patients. The use
of bevacizumab 15 mg/kg in the triplet cohort (83.0%) was greater
than use of bevacizumab 7.5 mg/kg dose (17.0%). The median dose
of pemetrexed received was consistent with the product label rec-
ommendation (500 mg/m2).
3.2. OutcomesPFS (estimated via Kaplan–Meier analysis) differed across
Pem/Plat and matched treatment cohorts (P < 0.001, Table 3).
Pem/Plat patients had the highest median PFS (134 days), followed
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wig. 1. Cost effectiveness of Pem/Plat versus Pac/Carbo and Pac/Carbo/Bev. Abbreviat
emetrexed plus platinum; PFS, progression-free survival; vs, versus.
y triplet (126 days) and doublet patients (106 days). After adjust-
ent for smoking status, the Cox regression analysis showed that
em/Plat patients had a 33% lower risk of 1-year disease progres-
ion or death compared with doublet patients and a 32% lower risk
ompared with triplet patients. Pem/Plat patients had the highest
bserved median OS (298 days) compared with doublet (218 days,
 = 0.08) or triplet cohorts (271 days, P = 0.31) (Table 3).
Similar to the Pem/Plat cohort comparisons, Pem/Cis patients
ad the highest median PFS (128 days) compared with doublet (105
ays, P = 0.004) or triplet cohorts (112 days, P = 0.007) (Table 3).
fter adjustment for smoking status, the Cox regression analysis
howed a 30% lower risk of 1-year disease progression or death
ompared with doublet patients and a 34% lower risk compared
ith triplet patients. Pem/Cis patients had the highest observed
edian OS (327 days) compared with doublet (234 days, P = 0.10)
r triplet cohorts (279 days, P = 0.19) (Table 3).
The results of the pemetrexed plus cisplatin, ECOG PS 0/1 sub-
roup (median PFS of 132 days, or 4.3 months; median OS of 336
ays, or 11.0 months) were very similar to the outcomes observed
n the same population of the phase III clinical trial (median PFS
f 5.3 months; median OS of 11.8 months among patients with
denocarcinoma/large cell histology) [7]..3. Costs and cost effectiveness
As described in Table 4, costs for patients receiving Pem/Plat
ere higher compared with the doublet patients (difference ofev, bevacizumab; Carbo, carboplatin; OS, overall survival; Pac, paclitaxel; Pem/Plat,
$21,841 for PFS and $19,137 for OS, P ≤ 0.05). Patients receiving
Pem/Plat therapy had lower mean costs compared with patients
receiving triplet therapy (difference of $15,160 for PFS and $19,946
for OS, P ≤ 0.05). The same pattern was observed for patients receiv-
ing Pem/Cis therapy (Table 4).
Cost-effectiveness probabilities are shown in Fig. 1. The proba-
bility for Pem/Plat having higher costs/higher effectiveness versus
doublet therapy was 90.1% for PFS and 96.3% for OS.  The probability
for Pem/Plat having lower costs/higher effectiveness versus triplet
therapy was 69.5% for PFS and 85.0% for OS. A similar pattern was
observed for patients receiving Pem/Cis therapy (Fig. 2).
4. Discussion
This retrospective observational study used real-world,
nonclinical-trial data to evaluate the cost effectiveness of Pem/Plat
relative to two  other ﬁrst-line treatments for advanced nonsqua-
mous NSCLC. The cost effectiveness of pemetrexed in various
lines of therapy has been investigated using clinical trial data
and indirect comparisons that make use of these data [10–14].
From the US perspective, Klein et al. concluded that Pem/Cis may
be a cost-effective treatment for nonsquamous NSCLC patients.
Comparisons of Pem/Cis to the Pac/Carbo doublet resulted in an
ICER of $178,613 while the Pac/Carbo/Bev triplet compared to
Pem/Cis resulted in an ICER of $337,179 [10]. Our  study provides
additional context to these analyses, demonstrating that Pem/Plat
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cig. 2. Cost effectiveness of Pem/Cis versus Pac/Carbo and Pac/Carbo/Bev. Abbreviat
emetrexed plus cisplatin; PFS, progression-free survival; vs, versus.
s dominant when compared to Pac/Carbo/Bev triplet therapy, with
 longer median PFS of 8 days and non-signiﬁcanttly longer OS of
7 days for $15,160 and $19,946 less in costs over these periods,
espectively. When compared to Pac/Carbo doublet therapy, the
se of Pem/Plat was associated with a 28 day increase in PFS and
 non-signifcant increase of 80 days in OS, for an additional cost
f $21,841 and $19,137 over these two periods, respectively. The
robability of Pem/Plat having lower costs/higher effectiveness
ersus triplet therapy was 85.0% for OS while Pem/Plat had higher
osts/higher effectiveness versus doublet therapy in 96.3% of the
terations for OS.
The characteristics of patients in this study reﬂect a real-
orld patient population receiving ﬁrst-line treatment. Although
S tended to be good (71% of Pem/Plat patients had a PS of 0 or 1),
 relatively large number of patients had a PS of 2+, which differs
rom the clinical trial setting in which patients with poor PS may
e excluded.
Despite Pem/Plat patients receiving fewer mean cycles of ther-
py, PFS was longer for the Pem/Plat cohort compared with
ac/Carbo doublet or Pac/Carbo/Bev triplet; further evaluation is
arranted to identify possible drivers of this difference. Longer OS
as observed in patients on Pem/Plat compared with the doublet
r triplet. Similar PFS and OS results were observed in the Pem/Cis
ohort compared with the doublet or triplet.
A subgroup analysis of patients treated with Pem/Cis (approved
ombination in the ALIMTA® US Package Insert) showed resultsev, bevacizumab; Carbo, carboplatin; OS, overall survival; Pac, paclitaxel; Pem/Cis,
similar to those in the overall population of patients treated with
pemetrexed plus any platinum.
One consideration in using a convenient sample of patients
within a single oncology practice network is the potential for selec-
tion bias and homogeneity of care (that is, limited generalizability
of the results). However, the external validity of this study’s results
is supported by the similar outcomes observed in the phase III clin-
ical trials of ﬁrst-line treatment for advanced nonsquamous NSCLC
[6,7].
Several limitations of this study are acknowledged. No aca-
demic or government institutions were included, and therefore
these results may  not represent resource use and costs in all US
practice. Additionally, patients were only followed for one year post
index. Patients surviving beyond one year were censored at 1 year,
which may have resulted in an underestimation of survival across
the cohorts. Also, cost data for this study originated from the PMS
data and were limited to outpatient charges incurred within the
ION network. As such, we did not have complete cost data across
the entire continuum of treatment. For example, charges for inpa-
tient/emergency room services and other specialty care were not
available.5. Conclusion
In conclusion, the data from this study ﬁll an important need
for information regarding the relative value of these widely used
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reatment strategies in terms of cost effectiveness. Real-world
ata from a US oncology practice network in this study show
hat Pem/Plat can be considered cost effective compared with
ac/Carbo/Bev triplet. In comparison with the Pac/Carbo dou-
let, Pem/Plat is more costly, but the greater effectiveness and
otential incremental clinical beneﬁt may  be perceived as more
ost-effective, depending on payers’ or society’s willingness to pay.
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